SG11202005563YA - Inhibitors of fibroblast activation protein - Google Patents
Inhibitors of fibroblast activation proteinInfo
- Publication number
- SG11202005563YA SG11202005563YA SG11202005563YA SG11202005563YA SG11202005563YA SG 11202005563Y A SG11202005563Y A SG 11202005563YA SG 11202005563Y A SG11202005563Y A SG 11202005563YA SG 11202005563Y A SG11202005563Y A SG 11202005563YA SG 11202005563Y A SG11202005563Y A SG 11202005563YA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibitors
- activation protein
- fibroblast activation
- fibroblast
- protein
- Prior art date
Links
- 230000004913 activation Effects 0.000 title 1
- 210000002950 fibroblast Anatomy 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762599630P | 2017-12-15 | 2017-12-15 | |
| PCT/US2018/065859 WO2019118932A1 (en) | 2017-12-15 | 2018-12-14 | Inhibitors of fibroblast activation protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202005563YA true SG11202005563YA (en) | 2020-07-29 |
Family
ID=66815562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202005563YA SG11202005563YA (en) | 2017-12-15 | 2018-12-14 | Inhibitors of fibroblast activation protein |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11780821B2 (en) |
| EP (1) | EP3723753A4 (en) |
| JP (1) | JP2021506972A (en) |
| KR (1) | KR20200110653A (en) |
| CN (1) | CN112105354A (en) |
| AU (1) | AU2018386298B2 (en) |
| BR (1) | BR112020011862A2 (en) |
| CA (1) | CA3085803A1 (en) |
| IL (1) | IL275333B2 (en) |
| MX (1) | MX2020006128A (en) |
| RU (1) | RU2020122712A (en) |
| SG (1) | SG11202005563YA (en) |
| WO (1) | WO2019118932A1 (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2972577T3 (en) | 2016-12-14 | 2024-06-13 | Purdue Research Foundation | Imaging and therapy targeting fibroblast activation protein (FAP) |
| AU2018386298B2 (en) | 2017-12-15 | 2023-09-07 | Praxis Biotech LLC | Inhibitors of fibroblast activation protein |
| US11504364B2 (en) | 2018-12-21 | 2022-11-22 | Praxis Biotech LLC | Inhibitors of fibroblast activation protein |
| CA3124525A1 (en) * | 2019-01-04 | 2020-07-09 | Praxis Biotech LLC | Inhibitors of fibroblast activation protein |
| DK3891138T3 (en) | 2020-02-12 | 2022-04-04 | Philochem Ag | FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED ADMINISTRATION USES |
| IL295571A (en) * | 2020-02-12 | 2022-10-01 | Philochem Ag | Fibroblast activation protein ligands for targeted delivery applications |
| EP4146628A1 (en) * | 2020-05-06 | 2023-03-15 | Bayer Aktiengesellschaft | Pyridine (thio)amides as fungicidal compounds |
| EP4147053A1 (en) | 2020-05-07 | 2023-03-15 | Institut Curie | Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy |
| US20230295138A1 (en) * | 2020-06-04 | 2023-09-21 | Bayer Aktiengesellschaft | Heterocyclyl pyridines as novel fungicides |
| CN116745291A (en) | 2020-12-17 | 2023-09-12 | 阿斯利康(瑞典)有限公司 | N- (2- (4-cyanothiazolidin-3-yl) -2-oxoethyl) -quinoline-4-carboxamide |
| CN114790195B (en) * | 2020-12-21 | 2024-05-17 | 苏州药明博锐生物科技有限公司 | Fibroblast activation protein inhibitor |
| CN114790194B (en) * | 2020-12-21 | 2024-03-26 | 苏州药明博锐生物科技有限公司 | Fibroblast activation protein inhibitor |
| MX2023009486A (en) | 2021-02-12 | 2023-10-16 | Philochem Ag | Bivalent fibroblast activation protein ligands for targeted delivery applications. |
| EP4043452A1 (en) | 2021-02-12 | 2022-08-17 | Philochem AG | Bivalent fibroblast activation protein ligands for targeted delivery applications |
| CN113105432B (en) * | 2021-03-30 | 2022-03-04 | 上海交通大学医学院附属仁济医院 | Carbon-11 (C)11C) Radiopharmaceutical, preparation method and application thereof |
| TW202320805A (en) * | 2021-08-18 | 2023-06-01 | 美商杜夫特學院信託管理公司 | Radiofluorinated agents for pet imaging selectively targeting fibroblast activation protein |
| CN117460826A (en) * | 2021-09-14 | 2024-01-26 | 菲柏生物医学技术（广州）有限公司 | siRNA conjugate targeting FAP positive cells, and pharmaceutical composition and application thereof |
| MX2024004077A (en) | 2021-10-04 | 2024-04-18 | Philochem Ag | Radiolabelled fibroblast activation protein ligands. |
| CN113861111B (en) * | 2021-11-23 | 2023-05-26 | 浙江工业大学 | N-aryl-4-sulfur (selenium) ethyl multi-membered ring [ C ] -1-pyridone derivative and synthetic method and application thereof |
| WO2023144379A1 (en) | 2022-01-30 | 2023-08-03 | Philochem Ag | High-affinity ligands of fibroblast activation protein for targeted delivery applications |
| CN115304582B (en) * | 2022-07-20 | 2023-05-12 | 北京法伯新天医药科技有限公司 | FAP-alpha specific tumor diagnostic imaging agent |
| WO2024052333A1 (en) | 2022-09-06 | 2024-03-14 | Philochem Ag | Multivalent fibroblast activation protein ligands for targeted delivery applications |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0010188D0 (en) | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
| TW583185B (en) | 2000-06-13 | 2004-04-11 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same |
| GB0115517D0 (en) | 2001-06-25 | 2001-08-15 | Ferring Bv | Novel antidiabetic agents |
| ES2291477T3 (en) | 2001-06-27 | 2008-03-01 | Smithkline Beecham Corporation | FLUOROPIRROLIDINS AS INHIBITORS OF DIPEPTIDIL PEPTIDASA. |
| US6861440B2 (en) | 2001-10-26 | 2005-03-01 | Hoffmann-La Roche Inc. | DPP IV inhibitors |
| HUP0200849A2 (en) | 2002-03-06 | 2004-08-30 | Sanofi-Synthelabo | N-aminoacetyl-pyrrolidine-2-carbonitrile derivatives, pharmaceutical compositions containing them and process for producing them |
| EP2319523A1 (en) | 2002-04-30 | 2011-05-11 | Trustees Of Tufts College | Serine protease inhibitors |
| WO2004071454A2 (en) | 2003-02-13 | 2004-08-26 | Guilford Pharmaceuticals Inc. | Substituted azetidine compounds as inhibitors of dipeptidyl peptidase iv |
| AU2006246719A1 (en) | 2005-05-19 | 2006-11-23 | Genentech, Inc. | Fibroblast activation protein inhibitor compounds and methods |
| CN101232873A (en) | 2005-08-11 | 2008-07-30 | 霍夫曼-拉罗奇有限公司 | Pharmaceutical composition comprising a dpp-iv inhibitor |
| EP1760076A1 (en) * | 2005-09-02 | 2007-03-07 | Ferring B.V. | FAP Inhibitors |
| CN101230058A (en) | 2007-01-23 | 2008-07-30 | 上海恒瑞医药有限公司 | Bicycle aza alkyl derivative, preparation method and use in medicine thereof |
| US8338450B2 (en) | 2007-09-21 | 2012-12-25 | Lupin Limited | Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors |
| EP2231687A4 (en) | 2008-01-10 | 2012-11-14 | Sun Pharma Advanced Res Co Ltd | Novel derivatives of acyl cyanopyrrolidines |
| EP2389176A4 (en) | 2009-01-23 | 2012-08-01 | Univ Sydney | Novel metabolic disease therapy |
| US9346814B2 (en) | 2012-01-17 | 2016-05-24 | Universiteit Antwerp | FAP inhibitors |
| EP2730571A1 (en) | 2012-11-12 | 2014-05-14 | Universitat De Barcelona | 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives |
| JP7032311B2 (en) | 2015-07-16 | 2022-03-08 | バイオエクセル セラピューティクス，インコーポレイテッド | New Techniques for Treating Cancer Using Immune Regulation |
| WO2017189569A1 (en) * | 2016-04-25 | 2017-11-02 | Trustees Of Tufts College | Multimediator dpp4 and fap inhibitors, and uses related thereto |
| ES2972577T3 (en) | 2016-12-14 | 2024-06-13 | Purdue Research Foundation | Imaging and therapy targeting fibroblast activation protein (FAP) |
| EP3554587B1 (en) | 2016-12-14 | 2022-03-30 | MedImmune, LLC | Embedded multiple-part sensor within a plunger rod to capture and transmit injection information |
| AU2018355222A1 (en) | 2017-10-23 | 2020-04-30 | The Johns Hopkins University | Imaging and radiotherapeutics agents targeting fibroblast-activation protein-α (FAP-α) |
| AU2018386298B2 (en) | 2017-12-15 | 2023-09-07 | Praxis Biotech LLC | Inhibitors of fibroblast activation protein |
| AU2019219057B2 (en) | 2018-02-06 | 2022-11-24 | Universität Heidelberg | FAP inhibitor |
| US11504364B2 (en) | 2018-12-21 | 2022-11-22 | Praxis Biotech LLC | Inhibitors of fibroblast activation protein |
| CA3124525A1 (en) | 2019-01-04 | 2020-07-09 | Praxis Biotech LLC | Inhibitors of fibroblast activation protein |
| CA3125929A1 (en) | 2019-01-11 | 2020-07-16 | Grunenthal Gmbh | Substituted pyrrolidine amides iii |
-
2018
- 2018-12-14 AU AU2018386298A patent/AU2018386298B2/en not_active Expired - Fee Related
- 2018-12-14 BR BR112020011862-1A patent/BR112020011862A2/en unknown
- 2018-12-14 SG SG11202005563YA patent/SG11202005563YA/en unknown
- 2018-12-14 US US16/221,398 patent/US11780821B2/en active Active
- 2018-12-14 CA CA3085803A patent/CA3085803A1/en active Pending
- 2018-12-14 MX MX2020006128A patent/MX2020006128A/en unknown
- 2018-12-14 IL IL275333A patent/IL275333B2/en unknown
- 2018-12-14 RU RU2020122712A patent/RU2020122712A/en unknown
- 2018-12-14 CN CN201880088252.0A patent/CN112105354A/en active Pending
- 2018-12-14 WO PCT/US2018/065859 patent/WO2019118932A1/en unknown
- 2018-12-14 JP JP2020552675A patent/JP2021506972A/en not_active Ceased
- 2018-12-14 EP EP18887574.4A patent/EP3723753A4/en not_active Withdrawn
- 2018-12-14 KR KR1020207020364A patent/KR20200110653A/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20190185451A1 (en) | 2019-06-20 |
| RU2020122712A (en) | 2022-01-18 |
| IL275333B2 (en) | 2023-09-01 |
| MX2020006128A (en) | 2020-09-21 |
| RU2020122712A3 (en) | 2022-01-18 |
| KR20200110653A (en) | 2020-09-24 |
| JP2021506972A (en) | 2021-02-22 |
| AU2018386298B2 (en) | 2023-09-07 |
| EP3723753A4 (en) | 2022-01-26 |
| BR112020011862A2 (en) | 2020-11-24 |
| IL275333A (en) | 2020-07-30 |
| EP3723753A1 (en) | 2020-10-21 |
| AU2018386298A1 (en) | 2020-07-30 |
| IL275333B1 (en) | 2023-05-01 |
| CN112105354A (en) | 2020-12-18 |
| US11780821B2 (en) | 2023-10-10 |
| CA3085803A1 (en) | 2019-06-20 |
| WO2019118932A1 (en) | 2019-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275333A (en) | Inhibitors of fibroblast activation protein | |
| IL269196A (en) | Novel inhibitors | |
| ZA201805879B (en) | Inhibitors of wdr5 protein-protein binding | |
| LT3700902T (en) | Inhibitors of trpc6 | |
| EP3898654A4 (en) | Inhibitors of fibroblast activation protein | |
| IL272649A (en) | Ahr inhibitors and uses thereof | |
| EP3142679A4 (en) | Peptide inhibitors of bcr-abl oligomerization | |
| IL304110A (en) | Inhibitors of keap1-nrf2 protein-protein interaction | |
| IL284434A (en) | Inhibitors of fibroblast activation protein | |
| ZA201907136B (en) | Ip6k inhibitors | |
| GB201708457D0 (en) | Inhibitors of metallo-beta-lactamases | |
| ZA201808238B (en) | Certain protein kinase inhibitors | |
| SG11202000621VA (en) | Inhibitors of ror? | |
| EP3555092A4 (en) | Protein kinase inhibitors | |
| SG10201913521TA (en) | Methods for enzymatic peptide ligation | |
| GB201709136D0 (en) | New therapeutic uses of enzyme inhibitors | |
| IL274550A (en) | Dopamine-b-hydroxylase inhibitors | |
| GB201708451D0 (en) | Inhibitors of metallo-beta-lactamases | |
| GB201706472D0 (en) | Tumour-targeting peptide variants | |
| GB201721465D0 (en) | Inhibitors | |
| GB201719989D0 (en) | Enzyme inhibitors | |
| GB201719886D0 (en) | Enzyme inhibitors | |
| GB201720189D0 (en) | Dopamine-B-hydroxylase inhibitors | |
| AU2017904351A0 (en) | Inhibitors of necroptosis | |
| GB201704922D0 (en) | Methods of protein stapling |